Who are we?
Kamada is focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Drugs Disributed by Kamada Ltd, Israel
Corticosteroid, β2 Agonist. Beclometasone Dipropionate Anhydrous 100 mcg/metered dose, Formoterol Fumarate (dihydrate) 6 mcg/metered dose. SOL. FOR INHAL.(with inhal. device): 120 actuat. Asthma: Maint. therapy for pts. 18 yrs. and above- 1, 2 inhal. ×2/d. max. dly. dose is 4 inhal. Maint. & reliever ther.: Pts. 18 yrs. and above- 1 inhal. ×2/d. max. dly. dose is 8 inhal.COPD: For pts. 18 yrs. and above- 2 inhal. ×2/d. See lit.
Asthma: Regular tmt. of asthma where use of a combin. product (inhaled corticost.&long-acting β2-agonist) is approp. Pts. not adequate. control. with inhal. corticoster. and ‘as needed’ inhal. rapid-act. beta2-agonist. Pts. already adequat. control. on both inhal. corticoster. and long-act. β2-agonist. COPD :Symptom. tmt. of pts. with severe COPD (FEV1 < 50% predicted normal) and a hist. of repeated exacerb., who have signific. sympt. despite regular ther. with long-act. bronchodilators.
C/I: Hypersens.
Human Normal Immunoglobulin 5 g/100 ml. VIALS: 1 x 2.5 g/50 ml, 5 g/100 ml, 10
g/200 ml. Dose depend. indicat. and
pharmacokinetic/clinic. response. See lit.
Replace. ther. in: Prim. immunodefic.
(congen. agammaglobulinem.,
hypogammaglobulinem., common
variable immunodefic.); Wiskott Aldrich
syndr. Myeloma/chron. lymphocytic leuk.
with severe second.
hypogammaglobulinem and recurr.
infects. Child with congen. AIDS and
recurr. infects.
C/I: Hypersens. See lit.
Alpha 1-antitrypsin (AAT) 1 g / 50 ml. VIAL (sol. for infus.): 1 x 50 ml. I.V. use
only. 60 mg/kg bdy. wt. 1 x wkly.
See lit.
Chron. augmentat./maint. ther. congen.
defic. alpha1-proteinase inhib. (Alpha1-
PI), also known as alpha1-antitrypsin
(AAT) defic. and clin. evidence
emphysema.
C/I: Immunoglobulin A (IgA) defic. with
antibodies against IgA. Hypersens., incl.
anaphylax. to Alpha1-PI product.
Blood Coagulant. Human Coagulation Factor VIII 250, 500, 1000 IU / vial. PWDR (I.V. INJECT.): 1+ solvent. See lit.
Tmt. and proph. bleed. in hemophil. A
(congen. factor VIII defic.) with acq. factor
VIII defic.
Anticoagulant. Heparin Sodium 10 IU/ml, 100 IU/ml. SINGLE DOSE VIAL: 10 IU/ml; 100 IU/ml x
20 x 10 ml. See lit.
Maint. potency I.V. device. May be used
foll. initial placement of device in vein or
aft. withdrawal of blood lab. analysis.
C/I: Hypersens., severe
thrombocytopen., uncontrolled active
bleed. See lit.
Human Hepatitis B Immunoglobulin 50 IU/ml. AMPS: 2 ml.
VIALS: 10 ml, 40 ml. Aft. infect: 0.12 ml -
0.20 ml (6 IU - 10 IU)/kg bdy. wt. Proph.
(in high risk): Inject 0.14 ml (7 IU)/kg
bdy. wt. aft. screen. for HbsAg and
anti-HBs. Repeat at 2 mth. intervals.
See lit. Proph. in newborns og HBsantigen
positive mothers: 0.4 ml (20
IU)/kg bdy. wt. immed. aft. birth. See
lit.
Proph. against hepatit. B in adults and
child over 2 yrs. who have not been
vaccinat. against hepatit. B (incl. persons
whose vaccinat. is incomplete or missing),
at risk by accident. contact e.g. accident.
needle stick or direct mucous membrane
contact when admin. of I.M. hepatit.
immunoglob. is not possible. To be admin.
with hepatit. B vaccine. Immunoproph.
hepatit. B in newborn of hepatit. B virus
carrier mother.
C/I: Hypersens. to homologous
immunoglobulins.
